Current Medical Research and Opinion

Journal Information
ISSN / EISSN : 03007995 / 14734877
Current Publisher: Informa UK Limited (10.1080)
Former Publisher: Informa Healthcare (10.3111) , Informa Healthcare (10.1185)
Total articles ≅ 6,781
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Cristina Stasi, Sinan Sadalla, Eleonora Carradori, Monica Monti, Luisa Petraccia, Francesco Madia, Laura Gragnani, Anna Linda Zignego
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1691517

The publisher has not yet granted permission to display this abstract.
Carol H. Wysham, Marjolaine Gauthier-Loiselle, Robert A. Bailey, Ameur M. Manceur, Patrick Lefebvre, Morris Greenberg, Mei Sheng Duh, James B. Young
Current Medical Research and Opinion pp 1-9; doi:10.1080/03007995.2019.1682981

The publisher has not yet granted permission to display this abstract.
Alejandro Salazar, Soledad Moreno, Helena De Sola, Jose Antonio Moral-Munoz, María Dueñas, Inmaculada Failde
Current Medical Research and Opinion pp 1-7; doi:10.1080/03007995.2019.1684251

The publisher has not yet granted permission to display this abstract.
Maria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, Miranda Peeples, Arielle G. Bensimon, Monica Macheca, Vivian Herrera
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1690440

The publisher has not yet granted permission to display this abstract.
Richard A. Chudleigh, Steve C Bain
Current Medical Research and Opinion pp 1-3; doi:10.1080/03007995.2019.1678344

Aleksandra Berkan-Kawińska, Anna Piekarska
Current Medical Research and Opinion pp 1-9; doi:10.1080/03007995.2019.1683817

The publisher has not yet granted permission to display this abstract.
Jae-A Park, Min-Young Lee, Jin Hyun Nam, Ju-Young Shin, Robert Wood, Tim Holbrook, Sun-Hong Kwon
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1688271

The publisher has not yet granted permission to display this abstract.
Heng Fan, Jun Xiao
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1687432

The publisher has not yet granted permission to display this abstract.
Esther Pogatzki-Zahn, Peter Kranke, Judit Winner, Wolfgang Weyland, Alexander Reich, Ursula Vigelius-Rauch, Michael Paland, Thorsten Löhr, Leopold Eberhart
Current Medical Research and Opinion pp 1-8; doi:10.1080/03007995.2019.1681133

The publisher has not yet granted permission to display this abstract.
Leslie R. Harrold, Ying Shan, Sean E. Connolly, Evo Alemao, Sabrina Rebello, Lin Guo, Joel M. Kremer
Current Medical Research and Opinion pp 1-6; doi:10.1080/03007995.2019.1680354

Abstract:Objective: To characterize the rate of healthcare resource utilization (HCRU) between anti-cyclic citrullinated peptide (CCP; a surrogate for anti-citrullinated protein antibodies [ACPAs]) positive (+) patients with rheumatoid arthritis (RA), either with or without erosions, who initiated biologic disease-modifying antirheumatic drug (bDMARD) treatment. Methods: Data from the Corrona RA registry, a prospective registry of adult patients with RA from 177 sites across 42 states in the US, were analyzed. Annual rates of HCRU (measured based on rates of all-cause hospitalization, joint surgery, imaging procedures and use of assistive devices) were estimated in anti-CCP + patients with and without erosions following bDMARD initiation using a Poisson regression model. Results: Among the 3333 patients with known anti-CCP and erosion status and 12-month post-bDMARD follow-up information in the Corrona registry, 2047 were anti-CCP + and included in this analysis; 868 with and 1179 without erosions. Baseline characteristics were generally well balanced between patients with and without erosions; however, those with erosions had a longer mean RA duration and a higher prior DMARD use. Over 12 months, among anti-CCP + patients, those with erosions had significantly higher rates of all HCRU, except joint surgery, than those without erosions. Age-adjusted risk ratios (95% confidence interval) were as follows: all-cause hospitalization, 1.47 (1.14, 1.90); all-cause imaging, 1.25 (1.03, 1.53); and assistive device use 1.12 (1.00, 1.25). The rate of joint surgery visits was also numerically higher in patients with versus without erosion. Conclusions: ACPA seropositivity with erosive disease was associated with higher rates of HCRU compared with seropositivity without erosions. These findings suggest that providers may want to manage anti-CCP + patients aggressively to achieve better disease control to prevent the development of erosions and the associated increase in HCRU.